Patient Preference or Indifference: Learning from the CABADOC Study

Affiliations

¹ The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; The Garvan Institute for Medical Research, Darlinghurst, Australia; St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia.
² Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia; Westmead Clinical School, University of Sydney, Westmead, Australia; Macquarie University, Macquarie Park, Australia.
³ The Centre for Medical Psychology & Evidence-based Decision-Making, School of Psychology, Faculty of Science, The University of Sydney, Camperdown, Australia; The Psycho-Oncology Cooperative Research Group, School of Psychology, Faculty of Science, The University of Sydney, Camperdown, Australia.
⁴ The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; The Garvan Institute for Medical Research, Darlinghurst, Australia; St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia. Electronic address: m.crumbaker@garvan.org.au.

Editorial

Anthony M Joshua et al. Eur Urol. 2022 Mar.

. 2022 Mar;81(3):241-242.

doi: 10.1016/j.eururo.2021.11.005. Epub 2021 Nov 23.

¹ The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; The Garvan Institute for Medical Research, Darlinghurst, Australia; St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia.
² Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia; Westmead Clinical School, University of Sydney, Westmead, Australia; Macquarie University, Macquarie Park, Australia.
³ The Centre for Medical Psychology & Evidence-based Decision-Making, School of Psychology, Faculty of Science, The University of Sydney, Camperdown, Australia; The Psycho-Oncology Cooperative Research Group, School of Psychology, Faculty of Science, The University of Sydney, Camperdown, Australia.
⁴ The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; The Garvan Institute for Medical Research, Darlinghurst, Australia; St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia. Electronic address: m.crumbaker@garvan.org.au.

No abstract available

Comment on

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, Maillard A, Martineau G, Borget I, Fizazi K; Groupe d’Etude des Tumeurs Uro-Genitales (GETUG).. Baciarello G, et al. Eur Urol. 2022 Mar;81(3):234-240. doi: 10.1016/j.eururo.2021.10.016. Epub 2021 Nov 14. Eur Urol. 2022. PMID: 34789394 Clinical Trial.